Nkarta – Talk Bio

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

1 month ago talkbio0Tagged Capitalization, clinical-stage biopharma, development aspects, exophthalmos producing substance, financial results, Impaired, Market, net loss, Nkarta, Operating expenses, Q3, research

Nkarta; Q3 2025 financial results; net loss; operating expenses; EPS; research and development; impairment; market capitalization; clinical-stage biopharma; corporate highlights

Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program

9 months ago talkbio0Tagged Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019, Cell Therapy, Nkarta, restructuring

Nkarta, restructuring, Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019, Cell Therapy

Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs

1 year ago talkbio0Tagged Autoimmune Diseases, Automobiles, Cancer Programs, deprioritization, Lupus Nephritis, NK cell therapy, Nkarta

Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization